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Abstract
Background: Hyperosmolar therapy, using either mannitol or hypertonic saline (HTS), is considered the treatment of
choice for intracranial hypertension. However, hyperosmolar agents may impair coagulation and platelet function, limiting
their use in patients at risk for hemorrhage. Despite this, studies evaluating the effects of mannitol compared to other
hyperosmolar agents in dogs are largely lacking. The aim of this study was to compare the in vitro effects on global
hemostasis and platelet function of 20 % mannitol and 3 % HTS on canine blood.
Methods: Citrated whole blood from 15 healthy dogs was diluted with 0.9 % saline, 20 % mannitol and 3 % HTS in ratios
of 1:16 and 1:8. Rotational thromboelastometry (ROTEM) was used to assess clotting time (CT), clot formation time (CFT)
and maximal clot firmness (MCF) following extrinsic activation (Ex-tem) and after platelet inhibition (Fib-tem). A platelet
function analyzer (PFA-100) was used to assess closure time (CtPFA).
Results: No significant differences were observed between untreated whole blood and samples diluted with saline.
Samples diluted with both mannitol and HTS were hypocoagulable compared to untreated whole blood samples. At a
dilution of 1:16, no significant differences were found between any measured parameter in samples diluted with saline
compared to mannitol or HTS. At a 1:8 dilution, CtPFA was prolonged in samples diluted with mannitol and HTS
compared to saline, and CtPFA was prolonged more with mannitol than HTS. Ex-tem CT was increased at a 1:8
dilution with mannitol compared to HTS. Ex-tem CFT was prolonged at a 1:8 dilution with both agents compared
to saline, and was prolonged more with mannitol than HTS. Ex-tem MCF was reduced at a 1:8 dilution with both
agents compared to saline.
Discussion and Conclusions: Data in this study indicate that both mannitol and HTS affect canine platelet
function and whole blood coagulation in vitro in a dose-dependent fashion. The most pronounced effects were
observed after high dilutions with mannitol, which impaired platelet aggregation, clot formation time, clot
strength, and fibrin formation significantly more than HTS. Further in vivo studies are necessary before
recommendations can be made.
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Background
Hyperosmolar therapy has been used for decades to treat
intracranial hypertension in both human and veterinary
medicine [1–3]. Mannitol has been the primary hyperos-
molar agent used since the 1960s and concentrations of 15
to 20 % have been shown to have beneficial effects on
intracranial pressure, cerebral perfusion pressure and cere-
bral blood flow, as well as on brain metabolism [3, 4].
Hypertonic saline (HTS) solutions of different strengths
have been used as alternative agents to mannitol and have
been shown to reduce intracranial pressure, and improve
cerebral blood flow and oxygen delivery [2, 5, 6]. Indeed,
numerous reports have suggested that 7.5 % HTS may be
superior to mannitol for the treatment of intracranial
hypertension in both humans and dogs [7–11]. However,
several studies have shown that both mannitol and HTS
interfere with coagulation and platelet function in humans,
which may limit their use in some patients [12–15]. Pro-
posed mechanisms of impaired hemostasis include dilu-
tional coagulopathy, platelet dysfunction, diminished clot
propagation and clot strength, as well as impaired fibrin
formation [12–14]. Dogs with severe traumatic brain injury
or pre-existing coagulopathies may therefore be at in-
creased risk of hemorrhage after administration of hyper-
osmolar agents.
Although several studies have investigated the
hemodynamic effects of hyperosmolar agents in dogs
with hemorrhagic, traumatic, endotoxic, and hypovol-
emic shock, only few studies have investigated their ef-
fects on coagulation in dogs [16–23]. A recent in vitro
study in dogs found that 7.2 % HTS and hypertonic
hydroxyethyl starch impair platelet aggregation as well
as parameters of global coagulation measured using ro-
tational thromboelastometry (ROTEM) [24]. Another
study found no deviation from reference intervals in
platelet counts, prothrombin time and partial thrombo-
plastin time following infusion with 7.5 % HTS com-
bined with colloids (dextran or hydroxyethyl starch) in
a canine hemorrhagic shock model [25]. However, no
study has evaluated the effects of mannitol on coagula-
tion and platelet function compared to other hyperos-
molar agents in dogs, and the relative risk of impaired
hemostasis following administration of these agents is
largely unknown. Despite this, these agents are used in
practice and dosage recommendations have been pub-
lished [1, 2, 26–28]. Knowledge of the extent to which
different hyperosmolar agents may impair global
hemostasis or platelet function may influence clinical
decisions in the selection of agents to treat individual
dogs based on a perceived risk of hemorrhagic compli-
cations. The purpose of this study was to investigate
and compare the in vitro effects of 20 % mannitol and
3 % HTS on canine platelet function and whole blood
coagulation.
Methods
The study was designed as an experimental non-
randomized comparative in vitro study. The protocol
was approved by the University of Bern and the Ani-
mal Experiment Committee of the Swiss Federal Vet-
erinary Office (BE 110/12) and all dog owners gave
written permission for blood sampling.
Animals
Fifteen healthy, staff- and student-owned dogs were in-
cluded in the study. All dogs weighed >15 kg to ensure a
large vessel diameter for adequate blood flow into the
blood collecting tubes. Dogs were considered to be
healthy based on physical examination and unremark-
able findings of a complete blood count and serum bio-
chemical analyses. Dogs were excluded if there was a
history of a bleeding disorder, chronic or current illness,
or the administration of drugs within 4 weeks prior to
the study. The dogs had a mean age of 3.8 years (range,
1.0 to 9.5 years). Eight dogs were female (four sexually
intact; four spayed) and seven were male (five sexually
intact; two castrated). Food was withheld from all dogs
for 10 h prior to blood collection.
Sample collection
Blood (13.4 ml) was obtained from each dog by lateral
saphenous venipuncture using a 21-gauge needle and
distributed directly under continuous blood flow into
blood tubes in the following order: 1 ml into a lithium-
heparin tube (Sarstedt AG, Switzerland) for biochemical
analyses, 3.8 ml into each of three buffered 3.8 % sodium
citrate tubes (S-Monovette for PFA-100, Sarstedt AG,
Switzerland) for platelet function analysis (PFA-100) and
rotational thromboelastometry (ROTEM), and 1 ml into
an EDTA tube (Sarstedt AG, Switzerland) for a complete
blood count. Immediately following collection, the tubes
were inverted carefully to ensure adequate mixing. The
blood was maintained at room temperature and all ana-
lyses were carried out within 3 h of blood collection (im-
mediate analysis of all samples was not possible due to
the number of samples and time necessary for ROTEM
analyses).
Sample preparations and measurements
Measurement of baseline values for PFA-100 and ROTEM
were performed in undiluted blood samples from each
dog. In addition, aliquots of each blood sample were di-
luted with 3 % HTS (3 % sodium chloride solution,
Dr. Grogg Chemie AG, Switzerland), 20 % mannitol (20 %
mannitol, Laboratorium Dr. G. Bichsel AG, Switzerland),
and saline (0.9 % sodium chloride solution, Fresenius Kabi
AG, Switzerland) in dilutions of 1:16 (6.25 vol. % dilution,
i.e. 1 part study solution and 16 parts blood) and 1:8
(12.5 vol. % dilution). All samples were mixed gently and
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incubated at room temperature prior to analyses. All
PFA and ROTEM analyses were performed as single
measurements.
Whole blood coagulation
Whole blood coagulation was analyzed by rotational
thromboelastometry (ROTEM®, TEM Innovation GmbH,
Munich, Germany) according to the manufacturer’s in-
structions using methods previously described for canine
samples [29]. Briefly, a 300 μL sample of citrated whole
blood was added to the clotting reagents in the pre-
warmed cuvette using the supplied electronic pipette. The
assays used were Star-tem, Ex-tem and Fib-tem (Tem
Innovation GmbH, Munich, Germany): After recalcifica-
tion with Star-tem reagent, coagulation was initiated by
the extrinsic pathway by addition of Ex-tem reagent
(recombinant tissue factor), and by the extrinsic pathway
by addition of Ex-tem reagent with re-calcification and
platelet inhibition by cytochalasin D using the Fib-tem re-
agent. The clotting reactions were assessed using the manu-
facturer’s data processing software. Data obtained included
clotting time, CT (the time from initiation of the reaction
until onset of clotting), clot formation time, CFT (the time
from the onset of clotting until clot firmness reaches ampli-
tude of 20 mm) and maximal clot firmness, MCF (the max-
imum amplitude of the thromboelastogram curve).
Platelet function
Platelet function was analyzed using a platelet function
analyzer (PFA-100®, Siemens Healthcare Diagnostics AG,
Zurich, Switzerland). The analysis was performed using
methods previously described for canine blood [30,
31]. Briefly, collagen/adenosine-5-diphosphate (CAPD)
cartridges (Dade® PFA Collagen/ADP Test Cartridge,
Siemens Healthcare Diagnostics, AG, Zurich, Switzerland)
were warmed to room temperature and 0.8 mL citrated
whole blood was added. The sample was then aspirated
under constant vacuum from a reservoir through a capil-
lary and a microscopic aperture in a membrane, which is
coated with collagen and ADP. The PFA-100 measures
the closure time (CtPFA) in seconds, the time needed for
occlusion of the aperture by platelet plug formation.
Statistical analyses
All analyses were performed using commercial statistical
software (MedCalc version 12.7.7, MedCalc bvba, Ostend,
Belgium). Data sets were evaluated for normality using the
D’Agostino-Pearson test and by examining normal plots.
As some data sets were not normally distributed and
could not be transformed to normality, differences
between data in undiluted samples and samples with
various dilutions were analyzed using the Friedman test
and post-hoc Wilcoxon comparisons with Bonferroni
correction. Data for hematocrit and platelet counts are
reported as mean ± SD. Data for ROTEM and PFA are
displayed as median (interquartile range). Significance
was set at P < 0.05.
Results
Hematocrit and platelet counts
The complete blood counts revealed a mean hematocrit
of 49 ± 3.4 % (0.49 ± 0.034 l/l) and mean platelet count
of 252 ± 41 × 109/l.
Platelet Function - PFA
Baseline values of the 15 dogs were within the reference
range reported by Callan and Giger (52–86 s) [31], ex-
cept for one dog, which had a baseline value of 88 s.
A significant difference was found between samples
for CtPFA (F = 28.5, df = 6, P < 0.001) (Table 1, Fig. 1).
Pairwise comparisons revealed that, for 3 % HTS, only
the high dilution (1:8) resulted in significant prolonga-
tion of CtPFA compared to baseline (P = 0.002) or saline
(P = 0.002). In contrast, both dilutions with 20 %
mannitol resulted in significant prolongation of CtPFA
compared to baseline (P = 0.002). In addition, the
high dilution resulted in significant prolongation of
CtPFA compared to both saline (P = 0.002) and 3 %
HTS (P = 0.008) (Table 1, Fig. 1).
Whole blood coagulation - ROTEM
Baseline values of the 15 dogs were within reference
ranges reported by Falco at al. [32] and Smith et al. [29]
Ex-tem CT
A significant difference was found between samples for
Ex-tem CT (F = 5.8, df = 6, P < 0.001) (Table 1, Fig. 2).
Pairwise comparisons revealed that only samples diluted
with 20 % mannitol in both the 1:16 dilution (P = 0.006)
and 1:8 dilution (P = 0.019) differed significantly from
baseline. In addition, Ex-tem CT was increased in sam-
ples with 20 % mannitol compared to 3 % HTS in a 1:8
dilution (P = 0.042) (Table 1, Fig. 2).
Ex-tem CFT
A significant difference was found between samples for
Ex-tem CFT (F = 28.6, df = 6, P < 0.001) (Table 1, Fig. 3).
Pairwise comparisons revealed significant differences
from baseline in samples diluted with 3 % HTS, 1:8 dilu-
tion (P = 0.004), and with 20 % mannitol, 1:16 dilution
(P = 0.004) and 1:8 dilution (P = 0.002). Compared to
saline, Ex-tem CFT was only significantly more pro-
longed in samples with 1:8 dilutions of both 3 % HTS
(P = 0.002) and 20 % mannitol (P = 0.002). In addition, Ex-
tem CFT was more prolonged in samples with 20 % man-
nitol compared to 3 % HTS in 1:8 dilutions (P = 0.002) but
no significant difference was found between the samples
in 1:16 dilutions (Table 1, Fig. 3).
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Ex-tem MCF
A significant difference was found between samples for Ex-
tem MCF (F = 22.6, df = 6, P < 0.001) (Table 1, Fig. 4). Pair-
wise comparisons revealed that Ex-tem MCF was reduced
in samples with 1:8 dilutions of 3 % HTS (P = 0.002)
and 20 % mannitol (P = 0.002) compared to baseline. In
addition, a reduced MCF was found in 1:8 dilutions of
samples with 3 % HTS (P = 0.004) and 20 % mannitol
(P = 0.002) compared to saline. No difference was found
between 3 % HTS and 20 % mannitol in either dilution,
or between saline, 3 % HTS or 20 % mannitol in 1:16
dilutions (Table 1, Fig. 4).
Fib-tem CT
No significant differences were found between samples
for Fib-tem CT (F = 1.90, df = 6, P = 0.093) (Table 1).
Table 1 Thromboelastometry and platelet function analyses in undiluted blood samples and samples diluted with 0.9 % saline, 3 %
hypertonic saline, and 20 % mannitol in a ratio of 1:16 and 1:8 in 15 dogs
Variable Baseline
(undiluted)
0.9 % NaCl
(dilution 1:16)
0.9 % NaCl
(dilution 1:8)
3 % HTS
(dilution 1:16)
3 % HTS
(dilution 1:8)
20 % mannitol
(dilution 1:16)
20 % mannitol
(dilution 1:8)
PFA-100
CtPFA
(s)
60 (51–88) 73 (64–83) 72 (68–81) 77 (70–90) 108 (84–126)*,** 108 (89–132)* 172 (124–300)*,**,***
Ex-tem
CT (s) 35 (28–55) 38 (36–60) 44 (31–62) 37 (33–83) 40 (34–48) 51 (38–99)* 90 (46–134)*,***
CFT (s) 149 (131–159) 151 (128–184) 151 (123–175) 186 (148–206) 196 (176–
249)*,**
204 (158–249)* 252 (222–314)*,**,***
MCF
(mm)
59 (55–62) 56 (50–60) 55 (53–57) 54 (51–57) 50 (46–53)*,** 53 (51–56) 49 (45–50)*,**
Fib-tem
CT (s) 38 (30–43) 41 (33–51) 38 (32–47) 36 (32–42) 36 (32–43) 54 (28–66) 48 (38–58)
MCF
(mm)
8 (8–10) 7 (5–9) 7 (6–8) 7 (6–9) 7 (6–9) 7 (4–9) 5 (4–5)*,**,***
Values are presented as median (interquartile range) *significant difference (P < 0.05) compared with baseline; **significant difference (P < 0.05) compared with
0.9 % saline at the same dilution; ***significant difference (P > 0.05) compared with 3 % HTS at the same dilution. CtPFA closure time, CT clotting time, CFT clot
formation time, HTS hypertonic saline, MCF maximum clot firmness
Fig. 1 Box plots showing platelet function analyzer closure times (CtPFA) in undiluted blood samples and samples diluted with 0.9 % saline, 3 %
HTS, and 20 % mannitol in 1:16 and 1:8 dilutions
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Fig. 2 Box plots showing Ex-tem CT measurements in undiluted blood samples and samples diluted with 0.9 % saline, 3 % HTS, and 20 %
mannitol in 1:16 and 1:8 dilutions
Fig. 3 Box plots showing Ex-tem CFT measurements in undiluted blood samples and samples diluted with 0.9 % saline, 3 % HTS, and 20 %
mannitol in 1:16 and 1:8 dilutions
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Fib-tem MCF
A significant difference was found between samples for
Fib-tem MCF (F = 12.3, df = 6, P < 0.001) (Table 1,
Fig. 5). Pairwise comparisons revealed a significantly
reduced MCF in samples with 1:8 dilution of 20 %
mannitol (P = 0.004) compared to baseline. In addition,
Fib-tem MCF was significantly reduced with 1:8 dilu-
tion in samples with 20 % mannitol compared to 3 %
HTS (P = 0.004) and saline (P = 0.021) (Table 1, Fig. 5).
Discussion
Thromboelastometry using ROTEM is a dynamic ana-
lysis of specific aspects of the coagulation cascade
including clot formation, clot strength, and subsequent
fibrinolysis [29]. As platelet function is inhibited by cyto-
chalasin-D in the Fib-tem assay, this assay permits assess-
ment of fibrin polymerization alone. These methods
therefore provide information about the platelet function,
the interaction of platelets with the coagulation cascade,
fibrin polymerization, and clot lysis.
Both mannitol and HTS solutions are recommended for
the treatment of intracranial hypertension in dogs [2]. Re-
sults of the present study revealed that in vitro dilutions of
canine blood with 3 % HTS and 20 % mannitol, but not
with saline, affected ROTEM and PFA parameters in a
dose dependent fashion. Some of these effects were only
evident between samples diluted with 3 % HTS or 20 %
mannitol and undiluted samples. However, effects on the
measured parameters were also noted when comparing
samples at the high dilution (1:8) with 3 % HTS or 20 %
mannitol and those diluted with saline. These were an in-
creased CtPFA, prolonged CT and decreased MCF in the
Ex-tem profile in samples diluted with 3 % HTS, and
prolonged CtPFA, CFT Ex-tem, and decreased MCF in
the Ex-tem and Fib-tem profiles in samples diluted with
20 % mannitol. In addition, dilution with 20 % mannitol
lead to a prolonged CtPFA, CT, and CFT in Ex-tem, and
a decreased MCF in Fib-tem compared to 3 % HTS at
the high dilution.
The dilutions selected were chosen to mimic clinical
doses, assuming canine blood volumes of approximately
80 ml/kg [33]. The recommended initial bolus dose for
the treatment of intracranial hypertension is 5 ml/kg for
both 3 % HTS and 20 % mannitol (1 g/kg mannitol),
which corresponds to a 1:16 dilution [2], and a 1:8 dilu-
tion was chosen to examine changes at twice the initial
recommended bolus dose.
As both solutions are of similar osmolarity (20 % man-
nitol, 1098 mOsm/l; 3 % HTS, 1072 mOsm/l), differ-
ences between solutions were unlikely due to osmolarity
alone. The possible effects of HTS and mannitol on a
cellular level were not evaluated in the current study,
and flow cytometry or electron microscopy of platelets
might have added important information in regard to
platelet activation and platelet structure. Although 20 %
mannitol impaired blood coagulation to a greater extent
than 3 % HTS, this was only apparent in the high dilu-
tion (1:8), and no clear advantage of either solution was
Fig. 4 Box plots showing Ex-tem MCF measurements in undiluted blood samples and samples diluted with 0.9 % saline, 3 % HTS, and 20 %
mannitol in 1:16 and 1:8 dilutions
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found with regards to coagulation effects at the dose se-
lected to mimic a single bolus (1:16 dilution). Indeed, in
the present study many values were significantly differ-
ent from baseline and/or the dilutional control, but an
effect beyond the reference ranges reported by Smith at al.
[29] were only found after the high dilution (1:8) with
20 % mannitol for two parameters (CT and CFT Ex-tem)
and with 3 % HTS for one parameter (CFT Ex-tem). Data
in the present report does not therefore support any clear
advantage of one osmotherapeutic over the other. Never-
theless, findings in this study appear to corroborate results
from two previous in vitro human studies, which demon-
strated hypocoagulability caused by 15 % mannitol that
was more pronounced than that caused by 2.5 % HTS or
by a combination of hydroxyethyl starch with 15 % manni-
tol using ROTEM [12, 34].
A limitation to the present study is that all blood samples
were collected from healthy dogs and the analyses were
performed in vitro. The effects of osmotherapeutics on co-
agulation may be more pronounced in dogs with pre-
existing coagulopathies, and may also significantly differ in
vivo. Further studies are therefore necessary to evaluate the
true in vivo risk of hemostasis impairment following ad-
ministration of these agents in dogs with intracranial
hypertension and/or pre-existing coagulopathies.
Investigations into the pathophysiology of coagulation
impairing effects of hyperosmolar solutions are rare. Pos-
sible mechanisms for platelet dysfunction after hyperos-
molar therapy include osmotic shock and reduced platelet
calcium mobilization required for triggering platelet acti-
vation [35, 36]. In a recent human in vitro study, hyper-
tonic hydroxyethyl starch caused platelet dysfunction, and
deformed, activated and severely aggregated platelets, sus-
pected due more to the HTS component than the colloid
component of the solution [15]. In addition, hypernatre-
mia may impact plasmatic coagulation [14, 37], and im-
paired enzymatic function in the clotting cascade resulting
from an increased sodium ionic strength may contribute
to hypocoagulability [13]. Similar to other hypertonic solu-
tions, mannitol may cause hyperosmotic stress, resulting
in changes in platelet function and coagulation [14].
Lastly, recent research suggests that both 7.5 % HTS
and mannitol inhibit agonist-induced CD40L expres-
sion on platelets, which is a marker of platelet activa-
tion and inflammation [38].
Besides specific effects on coagulation, a certain degree
of dilutional coagulopathy may be expected after hyper-
tonic fluid administration. In vivo, this effect is due to
transcellular fluid shifts from the extravascular to the
intravascular space due to the osmotic pull of intravascu-
lar hypertonic agents (approximately 7 milliliter of free
water for every milliliter 7.5 % hypertonic saline infused)
[37]. These shifts result in increased intravascular volume
and subsequent dilution of the administered agent and re-
duced hypertonicity, as well as dilution of clotting factors
and platelets. Given the in vitro nature of the present
study, no redistribution of fluid can occur, resulting in di-
lution of clotting factors and platelets without reduction
Fig. 5 Box plots showing Fib-tem MCF measurements in undiluted blood samples and samples diluted with 0.9 % saline, 3 % HTS, and 20 %
mannitol in 1:16 and 1:8 dilutions
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of hypertonicity. Moreover, in vivo processes, such as buff-
ering and electrolyte homeostasis cannot occur. The re-
sults of this and other in vitro studies can therefore only
approximate in vivo conditions and the potential clinical
impact on hemostasis.
A further limitation to this study is that in vitro blood
dilutions of 10 and 20 % with mannitol have previously
been found to significantly decrease both hematocrit and
platelet counts in humans [39]. As CtPFA may be pro-
longed by a hematocrit below 25 % or platelet counts
below 100,000 platelets/μL, the observed effects of manni-
tol on CtPFA may be due only to hematocrit or platelet
lowering effects [31]. In contrast, blood dilution resulting
in decreased hematocrit is expected to result in hyperco-
agulable ROTEM tracings [39]. As platelet counts and he-
matocrits following dilutions were not measured in the
present study, the degree to which these may have affected
results is unclear. Moreover, the dilution of citrated blood
samples with the citrate-free study solutions may have re-
sulted in increased calcium concentrations following recal-
cification in the ROTEM cup. This in turn could impact
thrombin generation. However, as only minor changes were
observed following dilution with saline, these effects were
unlikely to impact results of this study.
Additional limitations to the present study relate to sam-
ple handling and stability. One limitation was that some of
the ROTEM measurements were started 2.5 h after blood
sampling due to the numbers of samples evaluated from
each blood draw. This is considerably longer than the
30 min recommended by Smith et al. [29]. Indeed, pro-
longed storage led to hypercoagulable TEG results in dogs
in a previous study [40], because canine blood undergoes
significant ex-vivo contact activation during and after
blood collection [29]. This prolonged storage time may
have affected ROTEM results in the present study. A fur-
ther limitation was that samples were stored at room
temperature (24 °C) and may have taken several minutes
to rewarm to 37 °C when added to the pre-warmed throm-
boelastometry cup [29]. This could result in temperature
inconsistencies, affecting ROTEM results. Lastly, duplicate
measurements could have mitigated some of the effects of
variabilities in sample handling on ROTEM results, but
this was not performed in the present study as it would
have doubled sample storage time.
Conclusion
In vitro dilution of blood with both mannitol and HTS
caused hypocoagulability and platelet dysfunction in a
dose-dependent fashion. The data in this study suggest
that at high dilutions mannitol causes a slightly greater
impairment of whole blood coagulation and platelet func-
tion than HTS. However, at low doses, simulating a clinic-
ally recommended dose, no difference was found in
coagulation effects between the two solutions. The results
of this in vitro study are difficult to extrapolate to an in
vivo situation because important elements such as trans-
cellular and vascular fluid shifts, and the intravascular and
interstitial spaces cannot be assed with an in vitro model.
Further studies on blood samples from dogs following
intravenous administration of these solutions are neces-
sary before recommendations can be made.
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